Industry Confident About Device Tax Repeal, But It's Still Vehicle-Shopping
AdvaMed CEO Scott Whitaker says he is as confident as ever that permanent device tax repeal will happen this year. The only question is, he suggests, what legislative vehicle will bring it over the finish line. User-fee and children's health-insurance reauthorizations are options, along with tax reform, he says.
You may also be interested in...
Capitol Hill Update: Congress Gets Reprieve On User Fee Passage, While AdvaMed Weighs Device Tax Options
Commissioner Gottlieb says the agency won't issue layoff notices "unless and until Sept. 30 passes without reauthorization" of US FDA user fee programs. Meanwhile, could the user fee bill be a vehicle for device tax repeal?
A group of top medical device executives led by AdvaMed CEO Scott Whitaker met the US commerce and health secretaries to discuss key industry issues, including device tax repeal, FDA user-fee reauthorization, trade policies and reimbursement.
The American Health Care Act, which passed the House by a narrow margin May 4, remains unpopular in the country and in the Senate, but the positive vote keeps it alive as a potential vehicle for permanent repeal of the device excise tax.